Modality
mRNA
MOA
IL-17i
Target
TROP-2
Pathway
PI3K/AKT
MDSTTR AmyloidosisBladder Ca
Development Pipeline
Preclinical
Aug 2017
→ Jan 2026
PreclinicalCurrent
NCT07977542
1,479 pts·Bladder Ca
2017-08→2026-01·Active
1,479 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-182mo agoInterim· Bladder Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Preclinical
Active
Catalysts
Interim
2026-01-18 · 2mo ago
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07977542 | Preclinical | Bladder Ca | Active | 1479 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |